{"id":536,"date":"2016-05-26T05:06:17","date_gmt":"2016-05-26T10:06:17","guid":{"rendered":"https:\/\/3sixtypharma.com\/?p=536"},"modified":"2016-05-26T07:53:53","modified_gmt":"2016-05-26T12:53:53","slug":"pipeline-biosimilar-asthma","status":"publish","type":"post","link":"https:\/\/3sixtypharma.com\/2016\/05\/26\/pipeline-biosimilar-asthma\/","title":{"rendered":"Pipeline biosimilar for asthma meets primary endpoint in P2\/3 study"},"content":{"rendered":"

\"Sorrento\"<\/a><\/p>\n

In Brief<\/span><\/p>\n

Biosimilar News<\/span><\/a> reports that Sorrento’s experimental anti-IgE biosimilar, STI-004, met it’s primary endpoint in a 32-week, Phase 2\/3 study conducted in China. ?Patients who received?STI-004 experienced?asthma exacerbation at a lower rate than those who received placebo: ?21% vs?55%.<\/span><\/p>\n

According to the Sorrento press release<\/a><\/span>, the patient population included both?adult and adolescents suffering from allergic asthma.<\/span><\/p>\n

Adverse Experiences<\/span><\/p>\n

The Biosimilar News article and Sorrento press release reported?that the adverse events (AEs) experienced during the study were similar to those reported for the?currently marketed product, Xolair?. ?However, AEs for?STI-004 and?PBO that were?observed?during the study were not reported.<\/span><\/p>\n

#3SixtyPharmaSME<\/span><\/p>\n

\n

Pipeline biosimilar shows promise: Anti-IgE biosimilar meets primary endpoint in Phase 2\/3 clinical trial for asthma https:\/\/t.co\/CPu7VKcDEZ<\/a><\/p>\n

— 3SixtyPharma (@3SixtyPharma) May 26, 2016<\/a><\/p><\/blockquote>\n